MAP2K7 and neuroblastoma: MEK inhibitors have shown variable activity as single agents in preclinical testing in NB (Hart et al., 2017; Umapathy et al., 2017), and the presence of amplified MYCN correlates with resistance to the MEK inhibitor binimetinib (Hart et al., 2017).